Marker may predict response to ipilimumab in advanced melanoma

February 4, 2014, American Association for Cancer Research

Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.

The study suggests combining immunotherapy with VEGF inhibitors, also known as angiogenesis inhibitors, may be a potential option for these .

The immune-checkpoint inhibitor ipilimumab works by boosting the body's immune system to combat melanoma. VEGF is a protein that promotes new blood vessel formation and growth, a process called angiogenesis, thus providing nutrients to the growing tumor. The study found that among patients who had late-stage melanoma, those who had high levels of VEGF in their blood prior to treatment with ipilimumab had decreased , poor overall survival outcomes, and were 60 percent more likely to die of their disease, compared with those who had lower levels of VEGF.

"VEGF is known to suppress the maturation of immune cells and their antitumor responses, and evidence points toward an association between high serum VEGF levels and poor prognosis in melanoma patients," said F. Stephen Hodi, M.D., director of the Melanoma Center at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School in Boston, Mass. "VEGF has also been shown to be a potential biomarker for other immunotherapies, thus it seemed logical to test the ability of VEGF to predict responses to ipilimumab.

"We found that VEGF may actually hinder some of the effects of the immune-checkpoint inhibitor," Hodi added. "We are beginning to better define predictive biomarkers for immune-checkpoint blockers, specifically ipilimumab. Our study further suggests that there is a potential interaction existing between the biology of angiogenesis and immune-checkpoint blockade."

Hodi and colleagues conducted retrospective analyses of blood samples collected from 176 patients with metastatic melanoma, before and after they were treated with ipilimumab, at Dana-Farber/Harvard Cancer Center and Memorial Sloan-Kettering Cancer Center. Patients were 16 to 91 years old, and the majority of them had stage 4 disease.

VEGF levels in patients' blood ranged from 0.1 to 894.4 picograms per milliliter (pg/ml). The investigators determined 43 pg/ml to be the cutoff value, and evaluated patient responses to treatment as those whose pretreatment VEGF levels were greater than (VEGF-high) or less than (VEGF-low) the cutoff value.

They found that at 24 weeks after starting ipilimumab treatment, 41 percent of the VEGF-low patients experienced clinical benefit, including partial or complete treatment responses; only 23 percent of the VEGF-high patients experienced a clinical benefit.

The median overall survival for VEGF-low patients was 12.9 months, compared with 6.6 months for VEGF-high patients.

The researchers found that while pretreatment VEGF levels had the potential to predict treatment outcomes, changes in VEGF levels during treatment were not linked to outcomes.

"It may be worthwhile to investigate combining immune-checkpoint inhibitors and angiogenesis inhibitors in advanced melanoma with high serum VEGF levels," said Hodi. His team has initiated a randomized clinical trial to test ipilimumab in combination with bevacizumab, an angiogenesis inhibitor, in patients with advanced melanoma.

Explore further: Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)

Related Stories

Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)

October 28, 2013
A University of Colorado Cancer Center study published in the journal PLOS ONE shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by ...

A culprit behind brain tumor resistance to therapy

March 5, 2012
Persistent protein expression may explain why tumors return after therapy in glioblastoma patients, according to a study published on March 5th in the Journal of Experimental Medicine.

FAK helps tumor cells enter the bloodstream

January 20, 2014
Cancer cells have something that every prisoner longs for—a master key that allows them to escape. A study in The Journal of Cell Biology describes how a protein that promotes tumor growth also enables cancer cells to use ...

VEGF may not be relevant biomarker for advanced prostate cancer

April 29, 2013
The well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers from the Department of Radiation Oncology at Thomas Jefferson University ...

High VEGF signaling score tied to lung cancer prognosis

February 22, 2012
(HealthDay) -- A high vascular endothelial growth factor (VEGF) signaling score correlates with good prognosis in patients with early squamous cell carcinoma (SCC) of the lung, according to a study published online Feb. 21 ...

Better treatment for brain cancer revealed by new molecular insights

July 9, 2012
Nearly a third of adults with the most common type of brain cancer develop recurrent, invasive tumors after being treated with a drug called bevacizumab. The molecular underpinnings behind these detrimental effects have now ...

Recommended for you

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Dietary fat, changes in fat metabolism may promote prostate cancer metastasis

January 15, 2018
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.